

Aptar Pharma Multidose Device Delivers Approved Human Monoclonal Antibody Anti-COVID Nasal Spray in Thailand

Crystal Lake, Illinois, December 20, 2022 - Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP7 nasal multidose device is the delivery system for Hibiocy's VAILL COVITRAP™ Anti-CoV nasal spray, which was recently approved by the Thailand Food and Drug Administration (FDA).

The VAILL COVITRAP™ Anti-CoV nasal spray has been developed and classified as a medical device through the joint efforts of Chulalongkorn University, Silpakorn University, the Health Systems Research Institute (HSRI), the Government Pharmaceutical Organization (GPO) and Hibiocy Co. Ltd., an affiliate of Roujukiss International PCL (KISS).



Image courtesy of Hibiocy Co. Ltd.

The nasal spray using Aptar Pharma's innovative VP7 multidose technology has been launched under the tradename "VAILL COVITRAP™ Anti-CoV Nasal Spray", a hypromellose-based (HPMC) nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibodies. The formulation provides a physical barrier on nasal mucosa that could prevent and/or trap viral particles and aid in the defense against the virus.

"This approval by the Thailand FDA makes our VP7 multidose pump technology a key component of this Anti-Covid nasal spray and further demonstrates Aptar Pharma's ability to help our customers develop and launch novel treatments that may help improve and save lives," stated Alex Theodorakis, President, Aptar Pharma Prescription.

"The discovery behind the development of this innovative respiratory-care medical device with the human monoclonal antibody for inhibiting COVID-19 is critical, given the continuing concern of the virus impacting daily life. We are delighted to have the technology behind the VP7 multidose nasal spray pump from Aptar Pharma for our product, the VAILL COVITRAP™ Anti-CoV Nasal Spray," said Worrawan Chaikamnerd, CEO at Hibiocy and KISS. "With proven technology, our product should be able to help protect patients from either becoming infected or reinfected with COVID-19."



Aptar Pharma's multidose VP7 nasal spray device is designed to enable reliable dosing and targeted medication delivery to the nasal mucosa and is used or in development for nasal drug delivery across a wide range of medical applications such as allergic rhinitis, pain and CNS, as well as intranasal antibodies, antivirals and vaccines.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

About Hibiocy Co. Ltd

Hibiocy Co. Ltd is a private corporation based in Bangkok, Thailand, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company. Hibiocy was established to lead the sourcing, procuring and manufacturing of healthcare products, with the VAILL COVITRAP™ Anti-CoV nasal spray being one of its product portfolios. Hibiocy is a newly established organization in Thailand that collaboratively works with key leading partners including Health Systems Research Institute (HSRI), the Faculty of Medicine at Chulalongkorn University, the Faculty of Pharmacy at Silpakorn University and the Government Pharmaceutical Organization (GPO) in jointly developing an anti-COVID nasal spray, a ground breaking innovation that is fully approved by the Thai FDA and commercialized since early October 2022. For more information, please visit <https://www.facebook.com/covitrap/>.

#



Press Release



Media Contact

Ciara Jackson

Aptar Pharma

+49 151 1951 6502

ciara.jackson@aptar.com